Analysts’ Weekly Ratings Changes for Alnylam Pharmaceuticals (ALNY)

A number of firms have modified their ratings and price targets on shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) recently:

• 6/29/2026 – Alnylam Pharmaceuticals had its price target lowered by HC Wainwright from $510.00 to $470.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Alnylam Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/21/2026 – Alnylam Pharmaceuticals was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/13/2026 – Alnylam Pharmaceuticals was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/4/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $510.00 price target on the stock.
• 5/19/2026 – Alnylam Pharmaceuticals is now covered by Citigroup Inc.. They set a “buy” rating and a $380.00 price target on the stock.
• 5/18/2026 – Alnylam Pharmaceuticals was upgraded by Citigroup Inc. to “strong-buy”.
• 5/5/2026 – Alnylam Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $510.00 price target on the stock.
• 5/4/2026 – Alnylam Pharmaceuticals was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 5/2/2026 – Alnylam Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/1/2026 – Alnylam Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $450.00 to $445.00. They now have an “outperform” rating on the stock.
• 5/1/2026 – Alnylam Pharmaceuticals had its price target raised by Wells Fargo & Company from $376.00 to $377.00. They now have an “equal weight” rating on the stock.

Insiders Place Their Bets

In related news, insider Melissa Mclaughlin sold 2,286 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the transaction, the insider directly owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This trade represents a 19.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. This trade represents a 70.77% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,740 shares of company stock valued at $2,420,214 over the last 90 days. 0.86% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.